Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry.

Circulation. Heart failure·2025
Same author

Left Ventricular Noncompaction Cardiomyopathy in Children: A Focus on Genetic and Molecular Mechanisms.

Reviews in cardiovascular medicine·2025
Same author

Transmembrane Protein 43: Molecular and Pathogenetic Implications in Arrhythmogenic Cardiomyopathy and Various Other Diseases.

International journal of molecular sciences·2025
Same author

Unraveling the genetic blueprint of doxorubicin-induced cardiotoxicity through systems genetics approaches.

Cardio-oncology (London, England)·2025
Same author

Genetic mapping of electrocardiographic parameters in BXD strains reveals Chromosome 3 loci to be associated with cardiac repolarization abnormalities.

Physiological genomics·2025
Same author

Unraveling the Genetic Blueprint of Doxorubicin-Induced Cardiotoxicity Through Systems Genetics Approaches.

Research square·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 15, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

拡張性心筋病変症 (Dilated cardiomyopathy) とは,心筋病変症の拡大を意味する.

John Lynn Jefferies1, Jeffrey A Towbin

  • 1Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.

Lancet (London, England)
|March 2, 2010
PubMed
まとめ
この要約は機械生成です。

拡張性心筋症は,心室の膨張とポンプ機能の障害を伴うため,心不全と突然死のリスクにつながる. 遺伝的要因と毒素が寄与し,患者の改善のために改善された治療戦略が必要になります.

さらに関連する動画

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

関連する実験動画

Last Updated: Jun 15, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

科学分野:

  • 心臓病学 心臓病学
  • 遺伝学 遺伝学とは
  • 病理生理学 病理生理学とは

背景:

  • 拡張性心筋症 (DCM) は,左心室の拡張と静脈動脈機能不全によって定義されます.
  • ダイアストリック機能障害,右心室機能障害,心不全まで進行する可能性があります.
  • 患者は心律不良,昏睡,突然の心臓死のリスクに直面します.

研究 の 目的:

  • 拡張性心筋病の主要な特徴,原因,および管理を要約します.
  • DCMに寄与する遺伝的および環境的要因を強調する.
  • 治療成果の改善の継続的な必要性を強調するためです.

主な方法:

  • 拡張性心筋症に関する既存の文献のレビュー.
  • 遺伝的および病因学的要因の分析.
  • 現在の治療方法と治療結果の要約.

主要な成果:

  • DCMは心臓の効率に影響を及ぼし,遺伝的要因は30~48%の症例に起因する.
  • 原因には,細胞骨格 / サルコメリックタンパク質の遺伝子変異,毒素,炎症 (例えば,心筋炎) が含まれる.
  • 子供では,ミトコンドリア機能障害と代謝の問題が関与しています.

結論:

  • 現在の治療法は,心臓の効率を高め,機械的ストレスを軽減することを目的としています.
  • アリズム障害の管理と突然死予防は極めて重要です.
  • 進歩にもかかわらず,拡張性心筋病の患者のアウトカムを改善することは,依然として優先事項です.